logo

Bioxcel Therapeutics, Inc. (BTAI)



Trade BTAI now with
  Date
  Headline
6/23/2020 7:14:31 AM BioXcel Therapeutics Appoints Reina Benabou As Chief Development Officer
6/16/2020 7:13:45 AM BioXcel Therapeutics Appoints William Kane As Chief Commercial Officer
6/11/2020 7:07:07 AM BioXcel Says First Patient Enrolled In Phase 1b/2 RELEASE Trial Of BXCL501 For Treatment Of Opioid Withdrawal Symptoms
5/12/2020 7:14:33 AM BioXcel Therapeutics Q1 Net Loss $14.9 Mln Vs Loss $7.2 Mln Last Year
2/20/2020 7:37:49 AM BioXcel Therapeutics Prices Public Offering Of 2 Mln Shares At $32/Shr
1/7/2020 7:06:01 AM BioXcel Therapeutics Enrolls First Patient In Phase 1b/2 Study Of BXCL501
12/30/2019 7:10:09 AM BioXcel Therapeutics Begins Pivotal Phase 3 Studies Of BXCL501
12/3/2019 7:03:13 AM BioXcel Therapeutics Prepares To Initiate Pivotal Phase 3 Studies With BXCL501
11/14/2019 7:14:26 AM BioXcel Therapeutics Q3 Loss Per Share $0.57 Vs Loss $0.31 Last Year
9/26/2019 9:21:59 AM BioXcel Prices Public Offering Of 2.30 Mln Shares At $8.25 Per Share
9/4/2019 8:13:35 AM BioXcel Receives FDA Orphan Drug Designation For BXCL701 For AML Treatment
7/22/2019 6:02:39 AM BioXcel Therapeutics' BXCL501 Meets Primary Endpoint In Phase 1b Placebo-Controlled Trial